XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://xconomy.com/boston/2020/08/31/early-bird-sale-for-xcelerate-at-biotech-week-boston-ends-this-friday/60%Monthly2020-08-31 21:15
https://xconomy.com/boston/2020/08/31/akcea-therapeutics-is-returning-to-parent-ionis-pharma-in-500m-buyout/60%Monthly2020-09-01 11:58
https://xconomy.com/san-francisco/2020/08/31/nestle-to-swallow-up-peanut-allergy-drug-maker-aimmune-in-2-6b-deal/60%Monthly2020-08-31 14:25
https://xconomy.com/national/2020/08/28/biotech-roundup-fda-culpa-tricida-trips-freenomes-funding-more/60%Monthly2020-08-28 17:37
https://xconomy.com/seattle/2020/08/27/athira-aims-for-the-nasdaq-to-advance-alzheimers-drug-to-phase-2-tests/60%Monthly2020-08-27 23:58
https://xconomy.com/new-york/2020/08/27/abbvie-urogen-overactive-bladder-treatment-misses-in-phase-2-trial/60%Monthly2020-08-27 21:30
https://xconomy.com/national/2020/08/27/national-xconomy-awards-digital-ceremony-complimentary-tickets-now-available/60%Monthly2020-08-27 12:40
https://xconomy.com/san-francisco/2020/08/26/kinnate-raises-98m-for-human-tests-of-targeted-cancer-therapies/60%Monthly2020-08-27 00:01
https://xconomy.com/san-francisco/2020/08/26/freenome-tacks-on-270m-to-advance-blood-tests-to-find-cancer-early/60%Monthly2020-08-26 23:17
https://xconomy.com/boston/2020/08/26/dyne-eyes-ipo-for-rd-of-genetic-medicines-for-rare-muscle-diseases/60%Monthly2020-08-26 17:47
https://xconomy.com/san-diego/2020/08/26/acadia-pharma-acquires-cersci-potential-pain-meds-in-52-5m-buyout/60%Monthly2020-08-26 12:55
https://xconomy.com/san-diego/2020/08/25/kura-oncology-adds-kyowa-kirins-stephen-dale-as-chief-medical-officer/60%Monthly2020-08-25 20:53
https://xconomy.com/san-francisco/2020/08/25/fda-rejects-tricida-chronic-kidney-disease-drug-more-data-needed/60%Monthly2020-08-25 20:43
https://xconomy.com/national/2020/08/24/fda-adds-plasma-as-2nd-covid-19-treatment-under-emergency-guidelines/60%Monthly2020-08-24 23:13
https://xconomy.com/boston/2020/08/24/yumanity-to-merge-with-proteostasis-to-advance-neuro-drug-pipeline/60%Monthly2020-08-24 18:56
https://xconomy.com/san-francisco/2020/08/21/astellas-reports-third-patient-death-in-audentes-gene-therapy-study/60%Monthly2020-08-21 19:44
https://xconomy.com/national/2020/08/21/bio-roundup-jj-buyout-biomarin-rebuffed-poseida-on-hold-more/60%Monthly2020-08-21 15:04
https://xconomy.com/national/2020/08/20/harmony-bio-and-inhibrx-raise-combined-247m-in-public-market-debuts/60%Monthly2020-08-21 06:58
https://xconomy.com/boston/2020/08/20/alzheon-lands-47m-to-take-another-shot-at-a-pivotal-alzheimers-test/60%Monthly2020-08-20 22:36
https://xconomy.com/national/2020/08/19/fda-rejects-biomarin-hemophilia-gene-therapy-asks-for-more-data/60%Monthly2020-08-19 22:49
https://xconomy.com/san-francisco/2020/08/19/kronos-bio-names-yasir-al-wakeel-as-its-first-chief-financial-officer/60%Monthly2020-08-19 22:23
https://xconomy.com/new-york/2020/08/19/jj-boosts-autoimmune-disease-drug-pipeline-with-6-5b-momenta-buyout/60%Monthly2020-08-19 23:44
https://xconomy.com/san-diego/2020/08/19/fate-therapeutics-taps-celgenes-dulac-as-its-chief-financial-officer/60%Monthly2020-08-19 17:08
https://xconomy.com/san-diego/2020/08/19/sorrento-therapeutics-cuts-ties-with-chief-financial-officer-jiong-shao/60%Monthly2020-08-19 16:32
https://xconomy.com/san-diego/2020/08/18/patient-death-in-poseida-prostate-cancer-study-prompts-clinical-hold/60%Monthly2020-08-19 00:03
https://xconomy.com/new-york/2020/08/18/axovants-paul-korner-named-chief-medical-officer-of-agile-therapeutics/60%Monthly2020-08-18 19:40
https://xconomy.com/san-francisco/2020/08/18/unity-biotech-arthritis-drug-flunks-phase-2-spelling-programs-end/60%Monthly2020-08-18 17:29
https://xconomy.com/san-francisco/2020/08/18/genentech-gets-fda-ok-for-injectable-rare-neuroimmune-disease-drug/60%Monthly2020-08-18 17:27
https://xconomy.com/boston/2020/08/17/tango-therapeutics-adds-175m-deal-turns-partner-gilead-into-investor/60%Monthly2020-08-18 01:39
https://xconomy.com/new-york/2020/08/17/bristol-myers-squibb-to-splash-out-475m-on-dragonfly-immunotherapy/60%Monthly2020-08-17 20:44
https://xconomy.com/europe/2020/08/17/sanofi-reaches-3-68b-deal-to-buy-principia-and-partnered-ms-drug/60%Monthly2020-08-21 14:20
https://xconomy.com/new-york/2020/08/14/advisory-body-backs-mesoblast-therapy-for-transplant-complication/60%Monthly2020-08-15 02:37
https://xconomy.com/europe/2020/08/14/curevacs-ipo-hauls-in-213m-as-key-mrna-covid-19-vaccine-test-nears/60%Monthly2020-09-29 21:19
https://xconomy.com/national/2020/08/14/bio-roundup-seres-soars-mesoblast-vote-duchenne-decision-more/60%Monthly2020-08-14 22:33
https://xconomy.com/new-york/2020/08/12/with-fda-nod-ns-pharma-duchenne-drug-becomes-sarepta-competitor/60%Monthly2020-08-13 19:28
https://xconomy.com/san-francisco/2020/08/12/perceptive-advisors-lianbio-inks-deals-with-bridgebio-myokardia/60%Monthly2020-08-12 20:34
https://xconomy.com/europe/2020/08/12/f2g-lands-60m-for-a-new-tack-on-taking-out-rare-fungal-infections/60%Monthly2020-08-12 16:53
https://xconomy.com/national/2020/08/12/pfizers-bourla-theres-coronavirus-vaccine-pressure-but-its-not-political/60%Monthly2020-08-12 12:58
https://xconomy.com/san-diego/2020/08/11/ligand-to-spend-438m-to-add-protein-maker-pfenex-to-technology-lineup/60%Monthly2020-08-11 17:33
https://xconomy.com/europe/2020/08/11/bayer-boosts-womens-health-drug-pipeline-paying-425m-for-kandy/60%Monthly2020-08-11 17:06
https://xconomy.com/national/2020/08/11/roche-gut-disease-drug-produces-mixed-results-in-late-stage-trials/60%Monthly2020-08-11 11:45
https://xconomy.com/boston/2020/08/10/seres-sets-sights-on-fda-after-c-diff-microbiome-therapy-scores-in-phase-3/60%Monthly2020-08-10 16:57
https://xconomy.com/national/2020/08/07/fda-green-lights-roche-spinal-muscular-atrophy-drug-first-oral-therapy/60%Monthly2020-08-07 23:50
https://xconomy.com/boston/2020/08/07/abbvie-exits-editas-alliance-pruning-another-genetic-medicines-pact/60%Monthly2020-08-07 19:49
https://xconomy.com/national/2020/08/07/bio-roundup-a-telehealth-combo-fdas-bcma-ok-biogens-bet-more/60%Monthly2020-08-07 15:38
https://xconomy.com/national/2020/08/07/moderna-pfizer-protocols-may-make-covid-vaccines-hard-to-compare/60%Monthly2020-08-07 12:54
https://xconomy.com/national/2020/08/06/glaxosmithkline-multiple-myeloma-drug-earns-fdas-first-anti-bcma-nod/60%Monthly2020-08-06 23:49
https://xconomy.com/raleigh-durham/2020/08/06/g1-vets-launch-arc-therapeutics-to-take-on-new-cancer-target/60%Monthly2020-08-06 17:49
https://xconomy.com/san-francisco/2020/08/06/biogen-to-pay-denali-1b-to-partner-on-parkinsons-drug-other-neuro-meds/60%Monthly2020-08-06 17:25
https://xconomy.com/new-york/2020/08/05/meiragtx-names-immunovants-zeldin-as-its-chief-medical-officer/60%Monthly2020-08-07 04:00
https://xconomy.com/san-francisco/2020/08/05/iggenix-grabs-10m-to-advance-antibody-treatments-for-allergies/60%Monthly2020-08-05 19:14
https://xconomy.com/new-york/2020/08/05/as-patients-pivot-to-telehealth-teladoc-livongo-plan-18-5b-tie-up/60%Monthly2020-08-05 18:52
https://xconomy.com/boston/2020/08/05/gentibio-joins-cell-therapy-chase-with-20m-and-new-treg-technology/60%Monthly2020-10-01 17:39
https://xconomy.com/boston/2020/08/04/black-diamond-makes-fang-nis-chief-business-officer-job-permanent/60%Monthly2020-08-05 02:35
https://xconomy.com/san-diego/2020/08/04/aspen-neuroscience-chief-scientific-officer-loring-to-step-down/60%Monthly2020-08-05 02:05
https://xconomy.com/san-diego/2020/08/04/prometheus-taps-conatuss-marshall-as-its-chief-financial-officer/60%Monthly2020-08-05 00:54
https://xconomy.com/national/2020/08/04/still-stuck-on-adhesion-issues-fda-rejects-dbvs-peanut-allergy-patch/60%Monthly2020-08-05 13:26
https://xconomy.com/san-francisco/2020/08/04/cymabay-pbc-drug-hits-phase-3-goals-with-signs-of-side-effect-advantage/60%Monthly2020-08-07 00:01
https://xconomy.com/boston/2020/08/04/abbvie-walks-from-voyager-rd-pact-spanning-alzheimers-parkinsons/60%Monthly2020-08-04 19:04
https://xconomy.com/new-york/2020/08/03/legend-biotech-ceo-xu-resigns-genscripts-zhang-named-successor/60%Monthly2020-08-03 21:32
https://xconomy.com/boston/2020/08/03/bluebirds-susanna-high-jumps-to-dyne-for-chief-operating-officer-role/60%Monthly2020-08-03 21:11
https://xconomy.com/europe/2020/08/03/morphosys-incyte-get-early-fda-nod-for-antibody-alternative-to-car-t/60%Monthly2020-08-06 22:35
https://xconomy.com/boston/2020/07/31/kymera-therapeutics-unveils-ipo-pitch-for-protein-degradation/60%Monthly2020-08-01 00:44